Data requirements for market authorization of biologics MCQs With Answer

Introduction

Data requirements for market authorization of biologics MCQs With Answer is designed to help M.Pharm students deepen their understanding of the regulatory dossier and evidence needed to obtain approval for biologic products. This set focuses on quality, safety and efficacy documentation — including CMC, non-clinical and clinical data — as well as requirements for characterization, viral safety, stability, comparability, immunogenicity assessment and post-approval pharmacovigilance. The questions reflect current regulatory expectations (CTD structure, WHO/ICH guidance, biosimilar-specific considerations) and emphasize practical aspects such as master cell bank documentation, potency assays and analytical method validation to prepare students for exams and regulatory roles.

Q1. Which dossier format is universally accepted for submission of biologics to major regulatory authorities and organizes information into modules including quality, non-clinical and clinical data?

• Common Technical Document (CTD) with Modules 1–5
• Electronic Common Submission Portal (ECSP) format
• Manufacturing Master File (MMF) only
• International Biological Summary (IBS)

Correct Answer: Common Technical Document (CTD) with Modules 1–5

Q2. Which document is essential in the CMC section to demonstrate control over the biologic manufacturing process and consistency between batches?

• Clinical study report
• Manufacturing process description and process control strategy including Master and Working Cell Bank documentation
• Labeling mock-up
• Marketing authorization letter

Correct Answer: Manufacturing process description and process control strategy including Master and Working Cell Bank documentation

Q3. Which of the following is considered a Critical Quality Attribute (CQA) for therapeutic proteins?

• Tablet hardness
• Glycosylation pattern and biological potency
• Container colour
• Marketing claims

Correct Answer: Glycosylation pattern and biological potency

Q4. For structural characterization of a recombinant monoclonal antibody, which analytical technique is most appropriate to confirm primary sequence and post-translational modifications?

• Mass spectrometry
• Thin-layer chromatography
• Optical microscopy
• Paper electrophoresis

Correct Answer: Mass spectrometry

Q5. Which set of studies is typically required to address viral safety of a biologic produced in mammalian cells?

• Viral clearance studies, adventitious agent testing, and characterization of cell banks
• Dermal irritation tests, eye irritation tests, and inhalation toxicity
• Only routine sterility testing
• Genotoxicity and carcinogenicity studies only

Correct Answer: Viral clearance studies, adventitious agent testing, and characterization of cell banks

Q6. Which information is mandatory for a Master Cell Bank (MCB) dossier section?

• Identity, purity, genetic stability, absence of adventitious agents and storage conditions
• Clinical trial enrollment criteria
• Sales forecasts and pricing strategy
• Physician prescribing habits

Correct Answer: Identity, purity, genetic stability, absence of adventitious agents and storage conditions

Q7. What types of stability data are normally required in the dossier to justify shelf life and storage conditions for a biologic?

• Long-term (real-time), accelerated and stress stability studies with defined acceptance criteria
• Only one temperature point for 3 months
• Weekly microbial sampling only
• Marketing survey of consumer preferences

Correct Answer: Long-term (real-time), accelerated and stress stability studies with defined acceptance criteria

Q8. When a manufacturer makes a significant change to the production process of a licensed biologic, what is typically required by regulators?

• A comparability exercise demonstrating that product quality, safety and efficacy are not adversely affected
• Only a notification with no supporting data
• Immediate market withdrawal
• Replacement of all prior batches without testing

Correct Answer: A comparability exercise demonstrating that product quality, safety and efficacy are not adversely affected

Q9. Which assessment is central to understanding immune responses against administered biologics during clinical development?

• Anti-drug antibody (ADA) testing and neutralizing antibody assessment
• Urine pregnancy test
• Complete blood count only
• Fecal occult blood test

Correct Answer: Anti-drug antibody (ADA) testing and neutralizing antibody assessment

Q10. For approval of a biosimilar, regulators usually require which combination of studies?

• Extensive analytical similarity, targeted non-clinical comparability and comparative clinical (PK/PD and at least one efficacy/safety) studies
• Only a marketing application without any studies
• Dietary surveys and patient preference studies
• Large-scale manufacturing without analytical comparison

Correct Answer: Extensive analytical similarity, targeted non-clinical comparability and comparative clinical (PK/PD and at least one efficacy/safety) studies

Q11. Which document addresses post-authorization safety monitoring and risk minimization activities for a biologic?

• Risk Management Plan (RMP) or Pharmacovigilance Plan
• Certificate of Pharmaceutical Product (CPP)
• Master Production Schedule
• Corporate social responsibility report

Correct Answer: Risk Management Plan (RMP) or Pharmacovigilance Plan

Q12. What is the primary purpose of a validated potency assay for a biologic product?

• To quantify the biological activity that correlates with the product’s clinical effect
• To measure tablet disintegration time
• To determine water content only
• To assess marketing potential

Correct Answer: To quantify the biological activity that correlates with the product’s clinical effect

Q13. When is an Environmental Risk Assessment (ERA) typically required in the marketing application for a biologic?

• When the product contains living organisms or is genetically modified, or when environmental exposure is possible
• Only for topical generics
• When the drug is supplied as a tablet
• For all small-molecule APIs under 100 mg dose

Correct Answer: When the product contains living organisms or is genetically modified, or when environmental exposure is possible

Q14. Which regulatory information about storage and shipping must be included in the biologic dossier?

• Recommended storage temperature range, cold-chain requirements and shipping conditions with validation data
• Only the manufacturer’s phone number
• Advertising materials for pharmacies
• Clinical investigator names

Correct Answer: Recommended storage temperature range, cold-chain requirements and shipping conditions with validation data

Q15. For batch release of a biologic, regulators commonly require which documents or evidence?

• Batch manufacturing records, quality control release tests, certificate of analysis and stability commitment
• Only the invoice and packing list
• Food safety certificates
• Patent filing documents

Correct Answer: Batch manufacturing records, quality control release tests, certificate of analysis and stability commitment

Q16. What is meant by “traceability” in the context of biologics market authorization and post-marketing surveillance?

• Ability to identify product batches, manufacturing history and distribution to enable linking adverse events to specific lots
• Tracking advertising spend
• Recording the number of marketing authorizations issued
• Monitoring competitor prices

Correct Answer: Ability to identify product batches, manufacturing history and distribution to enable linking adverse events to specific lots

Q17. What is the regulatory expectation for viral clearance studies submitted in a biologic dossier?

• Validated studies demonstrating adequate log reduction of model viruses using orthogonal inactivation/removal steps
• Only a statement that viruses are not present
• Visual inspection of cell cultures
• Marketing authorization from another country without data

Correct Answer: Validated studies demonstrating adequate log reduction of model viruses using orthogonal inactivation/removal steps

Q18. Which parameters are essential to include when validating analytical methods for a biologic’s release testing?

• Accuracy, precision, specificity, linearity, range and robustness
• Only the analyst’s name and signature
• Website traffic statistics
• Ingredient sourcing location

Correct Answer: Accuracy, precision, specificity, linearity, range and robustness

Q19. Under what condition can regulators allow extrapolation of additional therapeutic indications for a biosimilar without separate clinical trials for each indication?

• If similarity in mechanism of action, receptor interactions, pharmacokinetics, and immunogenicity is adequately demonstrated and scientifically justified
• If the biosimilar has a different amino acid sequence
• Only when the innovator has withdrawn the indication
• If the biosimilar manufacturer requests marketing exclusivity

Correct Answer: If similarity in mechanism of action, receptor interactions, pharmacokinetics, and immunogenicity is adequately demonstrated and scientifically justified

Q20. Which guidelines are commonly referenced by regulators and applicants for quality and viral safety of biologics during MA submission?

• ICH and WHO guidelines such as ICH Q5A/Q6B and WHO guidance on evaluation of similar biotherapeutic products
• Codex Alimentarius only
• Automotive industry safety standards
• International Labor Organization (ILO) employment rules

Correct Answer: ICH and WHO guidelines such as ICH Q5A/Q6B and WHO guidance on evaluation of similar biotherapeutic products

Download